Maginnis MS, Atwood WJ. JC Virus: an oncogenic virus in animals and humans? Semin Cancer Biol. 2009;19:261–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17:37–51.

Article  PubMed  Google Scholar 

Khalili A, Craigie M, Donadoni M, Sariyer IK. Host-immune interactions in JC virus reactivation and development of progressive multifocal leukoencephalopathy (PML). J Neuroimmune Pharmacol. 2019;14:649–60.

Article  PubMed  PubMed Central  Google Scholar 

Miyamura T, Jikuya H, Soeda E, Yoshiike K. Genomic structure of human polyoma virus JC: nucleotide sequence of the region containing replication origin and small-T-antigen gene. J Virol. 1983;45:73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gosert R, Kardas P, Major EO, Hirsch HH. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol. 2010;84:10448–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciardi MR, Zingaropoli MA, Iannetta M, Prezioso C, Perri V, Pasculli P, et al. JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. Virol J. 2020;17:23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatchwell E, Smith EB, Jalilzadeh S, Bruno CD, Taoufik Y, Hendel-Chavez H, et al. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. Front Neurol. 2022;13:1016377.

Article  PubMed  PubMed Central  Google Scholar 

Oshima Y, Tanimoto T, Yuji K, Tojo A. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler J. 2019;25:1141–9.

Article  CAS  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;2021: n71.

Article  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

Article  PubMed  PubMed Central  Google Scholar 

Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25:471–506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010;81:247–54.

Article  PubMed  Google Scholar 

Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.

Article  MathSciNet  PubMed  Google Scholar 

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

Article  PubMed  PubMed Central  Google Scholar 

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898.

Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

Article  PubMed  PubMed Central  Google Scholar 

Afanasiev V, Demeret S, Bolgert F, Eymard B, Laforêt P, Benveniste O. Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients. Neuromuscul Disord. 2017;27:251–8.

Article  PubMed  Google Scholar 

Alroughani R, Al Hashel J, Thussu A, Ahmed SF. Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait. Med Princ Pract. 2013;22:495–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beldi-Ferchiou A, Wahab A, Duchmann M, Hodel J, Patry I, Delfau-Larue M-H, et al. High effector-memory CD8+ T-cell levels correlate with high PML risk in natalizumab-treated patients. Mult Scler Relat Disord [Internet]. 2020;46. https://www.embase.com/search/results?subaction=viewrecord&id=L2007651415&from=export

Bellizzi A, Anzivino E, Ferrari F, Di Nardo G, Colosimo MT, Fioriti D, et al. Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn’s disease patients treated with infliximab. J Neurovirol. 2011;17:303–13.

Article  PubMed  Google Scholar 

Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of antibodies against JC virus in patients with refractory Crohn’s disease and effects of natalizumab therapy. Clin Gastroenterol Hepatol. 2015;13:1919–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertrand D, Chavarot N, Gatault P, Garrouste C, Bouvier N, Grall-Jezequel A, et al. Opportunistic infections after conversion to belatacept in kidney transplantation. Nephrol Dial Transpl. 2020;35:336–45.

Article  CAS  Google Scholar 

Biernacki T, Sandi D, Füvesi J, Fricska-Nagy Z, Kincses TZ, Ács P, et al. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLoS ONE [Internet]. 2022;17. https://www.embase.com/search/results?subaction=viewrecord&id=L2017817195&from=export.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–7.

Article  PubMed  Google Scholar 

Calabrese M, Pitteri M, Farina G, Bajrami A, Castellaro M, Magliozzi R, et al. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. J Neurol Neurosurg Psychiatry. 2017;88:1073–8.

Article  PubMed  Google Scholar 

Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Saccà F, et al. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. J Neuroimmunol. 2017;309:47–50.

Article  CAS  PubMed  Google Scholar 

Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler J. 2014;20:1381–90.

Article  CAS  Google Scholar 

Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361:1067–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics. 2020;17:200–7.

Article  CAS  PubMed  Google Scholar 

Cobo-Calvo A, Bau L, Matas E, Romero-Pinel L, Mañé Martínez MA, Majós C, et al. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis. Eur Neurol. 2015;73:220–9.

Article  CAS  PubMed  Google Scholar 

Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Natalizumab discontinuation in a Dutch real-world cohort. Mult Scler Relat Disord [Internet]. 2021;52. https://www.embase.com/search/results?subaction=viewrecord&id=L2012002266&from=export.

Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27–34.

Article  PubMed  Google Scholar 

Correia I, Batista S, Galego O, Marques IB, Jesus-Ribeiro J, Martins AI, et al. Long-term effectiveness and safety of natalizumab in a Portuguese population. Int Immunopharmacol. 2017;46:105–11.

Article  CAS  PubMed  Google Scholar 

Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Oliveira EML, Simm RF, Dasic G, de Morais MM, Perreira SLA, Callegaro D. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers. Arq Neuropsiquiatr. 2015;73:736–40.

Article  PubMed  Google Scholar 

Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, et al. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol. 2015;21:645–52.